论文部分内容阅读
目的探讨改良FOLFOX化疗方案与奥曲肽联合对乙型肝炎病毒相关性晚期肝癌治疗的效果及安全性。方法选取2013年8月-2015年7月收治的96例乙型肝炎病毒(HBV)相关性晚期原发性肝细胞癌(HCC)患者随机分为观察组与对照组,每组48例,对照组给予改良FOLFOX方案治疗,观察组在对照组基础上加用奥曲肽治疗,对比两组患者临床效果、1年生存率、生活质量及不良反应情况。结果两组患者均无完全缓解患者,观察组治疗有效率为66.7%,显著高于对照组的43.8%,差异有统计学意义(P<0.05);两组患者治疗后1年生存率比较差异无统计学意义;观察组生活质量改善有效率为79.2%,显著高于对照组的60.4%,差异有统计学意义(P<0.05);观察组白细胞下降发生率显著低于对照组,差异有统计学意义(P<0.05),胃肠道反应、肝脏损害以及口腔炎发生率比较差异均无统计学意义。结论改良FOLFOX方案联合奥曲肽用于HBV相关性HCC的治疗,能够有效改善临床治疗效果,提高患者生活质量,并能够在一定程度上减少部分不良反应及副作用,值得推广。
Objective To investigate the efficacy and safety of modified FOLFOX chemotherapy combined with octreotide in the treatment of hepatitis B virus-related advanced liver cancer. Methods Ninety-six patients with advanced hepatocellular carcinoma (HCC) related to hepatitis B virus (HBV) were randomly divided into observation group and control group from August 2013 to July 2015, with 48 cases in each group. Group was given modified FOLFOX regimen. The observation group was treated with octreotide on the basis of the control group. Clinical effect, 1-year survival rate, quality of life and adverse reactions were compared between the two groups. Results There was no complete remission in both groups. The effective rate of observation group was 66.7%, which was significantly higher than that of control group (43.8%) (P <0.05). The 1-year survival rates of two groups were significantly different (P <0.05). The incidence of leukopenia in the observation group was significantly lower than that in the control group, the difference was statistically significant Statistical significance (P <0.05), gastrointestinal reactions, liver damage and stomatitis incidence difference was not statistically significant. Conclusion The improved FOLFOX combined with octreotide for the treatment of HBV-related HCC can effectively improve the clinical effect and improve the quality of life of patients, and can reduce some adverse reactions and side effects to a certain extent, which is worth promoting.